DAEWOONG PHARMACEUTICAL
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Daewoong Pharmaceutical begins the first administration of the Bersiporocin, new treatment for idiopathic pulmonary fibrosis, as Phase II clinical trial 2023-02-06 13:00
Daewoong enters exclusive licensing agreement with CS Pharmaceuticals for Bersiporocin in Idiopathic Pulmonary Fibrosis in the Greater China Region 2023-01-31 14:43
Daewoong Pharmaceutical submitted NDA for its global new drug Fexuclue in 11 countries, only 1 year after approval in Korea 2023-01-26 09:14
Daewoong Pharmaceutical announces success in developing a new antidiabetic medication and its aims to enter the market in over 50 countries by 2030 2022-12-06 20:00
Daewoong Pharmaceutical Surpasses KRW 300 Billion in Q3 Revenue as Nabota Sales Grew by 93%, Leading Overall Growth in Revenue 2022-11-15 20:00
Daewoong Pharmaceutical Presents Phase 3 Clinical Trial Results of New Diabetes Treatment 'Enavogliflozin' and Roadmap to Enter 50 Countries by 2030 2022-11-02 09:00
CGBio Signing a North America Out-license Contract on "Novosis rhBMP-2," a Bone Substitute with Orthofix, USA 2022-08-04 21:00
Daewoong Pharmaceutical Co., Ltd. revs up the growth engine for Nabota, achieving the highest quarterly performance ever 2022-07-28 21:00
Daewoong Pharmaceutical Gets First Korean US FDA Fast-Track for New Idiopathic Pulmonary Fibrosis Drug 2022-07-20 21:00
Daewoong Pharmaceutical begins multinational phase 2 clinical trial for DWN12088, a new drug for idiopathic pulmonary fibrosis 2022-06-24 21:00
Daewoong Pharmaceutical announced first-quarter 2022 results 2022-05-05 21:00
HanAll Biopharma and Daewoong Pharmaceutical Invest in Turn Biotechnologies to Expand Growth Initiative 2022-04-13 08:00
/DISREGARD RELEASE: HanAll Biopharma and Daewoong Pharmaceutical/ 2022-04-12 15:34
Daewoong Pharmaceutical submitted NDA for its global new drug Fexuclue Tablets to the Philippines 2022-03-29 09:00
Daewoong Pharmaceutical Announces Successful Phase 3 Topline Results for New Antidiabetic Drug's Triple Combination Therapy 2022-02-25 22:00
HanAll Biopharma Appoints Almira Chabi as Chief Medical Officer and Chief Development Officer 2022-02-21 22:00
Daewoong Pharmaceutical Posts Record Annual Revenue in 2021, with Export Growth of Nabota and New Drug Development 2022-02-21 22:00
Daewoong Pharmaceutical Released Positive Phase 3 Topline Results for New Antidiabetic Drug 2022-01-25 22:00
HanAll Biopharma Reports Full-Year 2021 Results and Provides Business Update 2022-01-20 22:00
Daewoong's "Leaps and Bounds" Q3 Performance, Exceeds KRW 20B in Operating Income for Three Consecutive Quarters 2021-11-02 21:00
1 2 3 4